Ibrutinib has also been found to inhibit BMX (a non-receptor tyrosine kinase) mediate glioma stem cell (GSC)-derived pericyte growth and also disrupt the blood–tumor barrier, which augmented glioma-specific chemotherapeutic efficacy [82]. Here, NTRK1 is linked to central nervous system cancer.